Recent Updates
Recently added Catalysts
LUCD Positive Sentiment Score: 70/100

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

Key Takeaway: Lucid Diagnostics Inc. will hold a business update conference call and webcast on March 24, 2025, at 8:30 AM ET. The CEO, Lishan Aklog, will provide a business overview, while CFO Dennis McGrath will discuss the financial results for the fourth quarter of 2024. This event is part of their ongoing strategy to communicate business operations and growth to stakeholders.

Market Sentiment Analysis

POSITIVE FACTORS

  • Lucid Diagnostics is holding a business update to share growth strategies.
  • The call will offer insights into the company’s operations and financial results.
  • The company is focused on cancer prevention, targeting patients at risk.

Full Press Release Details

Conference Call and Webcast at 8:30 AM Eastern Time
NEW YORK, March 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Monday, March 24, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's fourth quarter 2024 financial results.
The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
SOURCE Lucid Diagnostics

21 %

more press release views with

Frequently Asked Questions

When is Lucid Diagnostics' conference call?

The conference call is scheduled for March 24, 2025, at 8:30 AM ET.

Who will speak during the conference call?

Lishan Aklog, M.D., and Dennis McGrath will present updates and financial results.

How can I access the conference call?

Call 1-800-836-8184 in the U.S. or 1-646-357-8785 internationally.

Where can I find the conference call replay?

The replay will be available for 30 days at luciddx.com under investor relations.

What does Lucid Diagnostics focus on?

Lucid specializes in cancer prevention related to gastrointestinal health, particularly GERD.

Last updated: Mar 10, 2025